Charybdotoxin

Discontinued Product

Charybdotoxin (Cat. No. 1087) has been withdrawn from sale for commercial reasons.
Cat.No. 1087 - Charybdotoxin | Glp-Phe-Thr-Asn-Val-Ser-Cys-Thr-Thr-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Gln-Arg-Leu-His-Asn-Thr-Ser-Arg-Gly-Lys-Cys-Met-Asn-Lys-Lys-Cys-Arg-Cys-Tyr-Ser-OH (Disulfide bridge: 7-28, 13-33 and 17-35) | CAS No. 95751-30-7
Description: KCa (BK) channel blocker
Alternative Names: ChTx
Datasheet
Citations (6)
Reviews
Literature (2)

Biological Activity

Specific inhibitor of the big conductance Ca2+-activated K+ channel.

Technical Data

M. Wt 4295.95
Formula C176H277N57O55S7
Sequence XFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS

(Modifications: X-1 = Glp, Disulfide bridge between 7 - 28, 13 - 33,17 - 35, Ser-37 = C-terminal OH)

Storage Desiccate at -20°C
CAS Number 95751-30-7
PubChem ID 102594130
InChI Key CNVQLPPZGABUCM-UHFFFAOYSA-N
Smiles [H]N1[C@@H](CCC1=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CC1=CNC4=C1C=CC=C4)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N3)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC2=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Asano et al (1993) Charybdotoxin-sensitive K+ channels regulate the myogenic tone in the resting state of arteries from spontaneously hypertensive rats. Br.J.Pharmacol. 108 214 PMID: 7679030

Gimenez-Gallego et al (1988) Purification, sequence, and model structure of charybdotoxin, a potent selective inhibitor of calcium activated potassium channels. Proc.Natl.Acad.Sci.U.S.A. 85 3329 PMID: 2453055

Miller et al (1985) Charybdotoxin, a protein inhibitor of single Ca2+ activated K+ channels from mammalian skeletal muscle. Nature 313 316 PMID: 2578618

View Related Products by Product Action

View all Calcium-Activated Potassium (KCa) Channel Blockers

Keywords: Charybdotoxin, Charybdotoxin supplier, K+, channel, blockers, high, conductance, Ca2+-dependent, Potassium, KCa, Channels, ca2+-activated, ca2+-dependent, venoms, ChTx, Ca2+-Activated, 1087, Tocris Bioscience

Reviews for Charybdotoxin

There are currently no reviews for this product. Be the first to review Charybdotoxin and earn rewards!

Have you used Charybdotoxin?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Ion Channel

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.